Immunization

Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants

Retrieved on: 
Monday, March 4, 2024

SAN CARLOS, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the completion of enrollment in its Phase 2 study evaluating VAX-24, a broad-spectrum, carrier-sparing 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), in healthy infants. Vaxcyte expects to announce topline safety, tolerability and immunogenicity data from the Phase 2 study primary three-dose immunization series by the end of the first quarter of 2025, followed by topline data from the booster dose by the end of 2025.

Key Points: 
  • Vaxcyte expects to announce topline safety, tolerability and immunogenicity data from the Phase 2 study primary three-dose immunization series by the end of the first quarter of 2025, followed by topline data from the booster dose by the end of 2025.
  • “Completing enrollment of the VAX-24 study with more than 800 healthy infants demonstrates yet another significant milestone in the development of our VAX-24 and VAX-31 PCV candidates,” said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte.
  • “We believe VAX-24 has a potential best-in-class profile for this vital population and is designed to cover more serotypes than any infant pneumococcal vaccine on-market or in U.S. clinics today.
  • “Given the significant burden of disease in young children, there remains a need for broader-spectrum vaccines like VAX-24 and VAX-31, our next-generation 31-valent PCV candidate, that are designed to provide greater protection than the current standard-of-care.”

Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, February 27, 2024

-- Significant Progress in Establishing Global Commercial Manufacturing Capacity for Vaxcyte's PCV Candidates, Including Expanded Collaboration with Lonza --

Key Points: 
  • ET / 1:30 p.m. PT --
    SAN CARLOS, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
  • Additionally, as part of ongoing Chemistry, Manufacturing and Controls (CMC)-focused discussions, Vaxcyte received encouraging input from the FDA regarding the VAX-24 adult licensure requirements.
  • The six-month safety data from both studies showed safety and tolerability results for VAX-24 similar to PCV20 at all doses studied.
  • Vaxcyte will host a conference call and webcast to discuss this announcement today, February 27, 2024, at 4:30 p.m.

Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO

Retrieved on: 
Wednesday, February 21, 2024

Mr. Papa succeeds Haywood Miller, who will step down from his role as interim CEO, effective February 21, 2024.

Key Points: 
  • Mr. Papa succeeds Haywood Miller, who will step down from his role as interim CEO, effective February 21, 2024.
  • "Following a thorough search process, we are pleased to appoint Joe Papa as president and CEO of Emergent,” said Zsolt Harsanyi, Ph.D., chairman of the Board of Directors.
  • “He is a recognized industry leader with unparalleled experience in all facets of the pharmaceutical and healthcare industry.
  • “I am confident that these important products provide for a bright future ahead as Emergent continues to lead in public health preparedness.

Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology

Retrieved on: 
Wednesday, February 21, 2024

ROCHESTER, N.Y., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease and cancer through the inhibition of SEMA4D, announces that it has entered into eight new antibody discovery agreements integrating use of its proprietary ActivMAb platform to select antibodies against difficult-to-drug transmembrane protein targets.

Key Points: 
  • ActivMAb’s new “Antigen Virus” application is a powerful complement to drug discovery strategies targeting complex protein targets including ion channels and G-protein coupled receptors (GPCRs) such as chemokine receptors.
  • We believe that this is a much more highly purified presentation and efficient selection technology than the complex natural membrane fragments that have been termed virus-like particles.
  • “We have recently publicized success in selecting high value antibodies against challenging multi-pass membrane targets.
  • We are excited to be able to capitalize on what we believe is recognition of the unique capabilities of our drug discovery technology.

GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise

Retrieved on: 
Thursday, March 7, 2024

GSK plc (LSE/NYSE: GSK) today announced additional funding and new data and resources under the COiMMUNITY Initiative to help achieve higher adult vaccination rates and health equity in the US and address ongoing barriers to adult immunization.

Key Points: 
  • GSK plc (LSE/NYSE: GSK) today announced additional funding and new data and resources under the COiMMUNITY Initiative to help achieve higher adult vaccination rates and health equity in the US and address ongoing barriers to adult immunization.
  • The COiMMUNITY Initiative complements recent industry and regulatory efforts to expand and improve adult vaccine availability, coverage and access.
  • GSK is equipping healthcare providers and their patients with simple tools to spur action and follow through on vaccination.
  • GSK will also continue to share new resources, tools and best practices in adult vaccine confidence and delivery via interactive webinars.

MEDI8897 (Nirsevimab): An Investigational Long-Acting Antibody that Protects all Infants through their First RSV Season with a Single Dose - Market Size, Forecasts, and Market Insight 2019-2032 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 27, 2024

The report provides comprehensive insights about MEDI8897 for Respiratory syncytial virus (RSV) in the seven major markets.

Key Points: 
  • The report provides comprehensive insights about MEDI8897 for Respiratory syncytial virus (RSV) in the seven major markets.
  • MEDI8897 (Nirsevimab) is an investigational long-acting antibody that protects all infants through their first RSV season with a single dose.
  • Nirsevimab is an immunization that provides direct prophylactic RSV protection to all infants via an antibody to help prevent LRTI caused by RSV.
  • A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of MEDI8897 in RSV.

New Study Shows Increase in Pharmacy Reimbursement Leads to Higher Adult Medicaid Flu Vaccination Rates

Retrieved on: 
Tuesday, February 27, 2024

The Global Healthy Living Foundation (GHLF) co-released a groundbreaking report that found a direct link between pharmacy reimbursement and flu vaccination rates among Medicaid-covered adults.

Key Points: 
  • The Global Healthy Living Foundation (GHLF) co-released a groundbreaking report that found a direct link between pharmacy reimbursement and flu vaccination rates among Medicaid-covered adults.
  • According to co-researcher Vibhu Tewary, Project Director, IQVIA Institute for Human Data Science, “a $13 increase in pharmacy reimbursement for adult flu vaccination was associated with a nearly 6 percent point surge in the state vaccination rate for Medicaid fee-for-service covered adults.”
    To put it in perspective, a mere $1 increment in Medicaid fee-for-service pharmacy reimbursement for adult flu vaccines translates to a half-percentage-point boost in vaccination rates.
  • Adults under Medicaid coverage often face significant disparities in vaccination rates compared to individuals with commercial insurance or Medicare coverage.
  • Research consistently shows that broadening pharmacy vaccination authority will increase immunization rates, reduce healthcare costs, and save lives.

Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas

Retrieved on: 
Tuesday, February 27, 2024

Takeda ( TSE:4502/NYSE:TAK ) and Biological E. Limited (BE), a leading India-based Vaccines and Pharmaceutical Company, today announced a strategic partnership to accelerate access to QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003) multi-dose vials (MDVs).

Key Points: 
  • Takeda ( TSE:4502/NYSE:TAK ) and Biological E. Limited (BE), a leading India-based Vaccines and Pharmaceutical Company, today announced a strategic partnership to accelerate access to QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003) multi-dose vials (MDVs).
  • These doses will ultimately be made available for procurement by governments in endemic countries by 2030 at the latest to support National Immunization Programs.
  • MDVs offer economic and logistical advantages for National Immunization Programs by minimizing packaging and storage expenses, while also reducing medical and environmental waste.
  • Together, we will help combat dengue on a global scale by significantly increasing manufacturing capacity for multi-dose vials of QDENGA to drive sustainable access to the vaccine in more endemic countries."

FINN PARTNERS LAUNCHES 'GLOBAL HEALTH IMPACT GROUP'

Retrieved on: 
Wednesday, March 6, 2024

NEW YORK, March 6, 2024 /PRNewswire/ -- FINN Partners announced today the formation of the "Global Health Impact Group" to marshal cross-practice policy, advocacy, and media expertise to advance issues and ideas that promote improved health outcomes and economic growth worldwide. The move harnesses the agency's full capabilities and sector expertise to address corporate, government and NGO public-health priorities in nearly 100 countries across Africa, Asia, Europe and the Americas.                                                          

Key Points: 
  • The FINN Global Health Impact Group is championed by Gil Bashe, Chair Global Health and Purpose, with support from Fern Lazar, managing partner, Global Health Lead; Amy Terpeluk, managing partner, CSR and Social Impact Lead; and Jessica Berk Ross, managing partner, Global Public Affairs Lead.
  • The Global Health Impact Group will work alongside the FINN Purpose and Social Impact Practice, which focuses on climate, diversity, environment, and sustainability priorities.
  • FINN Global Health Impact meets the needs of clients committed to solving issues at the intersection of climate and health."
  • The FINN Global Health Impact Group will do its part to head off the impact of those challenges."

Care Resource Receives $50,000 from Advance Auto Parts Foundation to Deliver Healthcare Services to Under-Resourced Communities in Broward County

Retrieved on: 
Tuesday, March 5, 2024

FORT LAUDERDALE, Fla., March 5, 2024 /PRNewswire/ -- Care Resource has launched a new mobile health unit, made possible by a generous $50,000 donation from the Advance Auto Parts Foundation.

Key Points: 
  • FORT LAUDERDALE, Fla., March 5, 2024 /PRNewswire/ -- Care Resource has launched a new mobile health unit, made possible by a generous $50,000 donation from the Advance Auto Parts Foundation.
  • This mobile health unit marks a significant advancement in the health center's mission to expand access to services in under-resourced communities throughout South Florida.
  • "Every person deserves the opportunity for a full, healthy life, which is why community health is a key pillar for our Advance Auto Parts Foundation.
  • By expanding health care services through mobile health units, Care Resource can further provide communities with the right care, at the right time, in the right place.